FTC Slams Gender Medicine Powerhouse

Federal Trade Commission building entrance sign

A powerful new lawsuit says a leading transgender health group helped sell risky, irreversible “treatments” to confused kids using false promises and hidden dangers.

Story Snapshot

Federal Trade Commission and four red states accuse WPATH of enabling false claims to sell child gender transitions
Lawsuit says group hid serious side effects and pushed puberty blockers, hormones, and surgeries as “medically necessary”
Standards allegedly dropped age limits and misled parents about suicide risk and medical consensus
Case tests how far government can go to stop deceptive “gender medicine” while Trump’s FTC backs parental rights

Federal Lawsuit Targets Transgender Standards That Shaped Kids’ Medical Care

The Federal Trade Commission, joined by Alaska, Iowa, Nebraska, and Texas, has filed a major lawsuit against the World Professional Association for Transgender Health, known as WPATH.^[1] The complaint says WPATH “provided the means” for clinics and hospitals to make false and unsubstantiated claims to parents while selling puberty blockers, cross-sex hormones, and surgeries to children.^[1] WPATH’s “Standards of Care” have been treated as the gold standard in gender medicine, guiding doctors, hospitals, insurers, and even government policies for years.^[5]

According to the lawsuit, that influence is exactly the problem.^[1] Federal regulators say WPATH’s guidance led parents to believe there was a strong medical consensus, solid evidence, and clear medical necessity behind these drastic interventions for minors, when the science was weak and the risks were downplayed.^[1]^[5] The Trump administration’s Federal Trade Commission argues that when parents are deciding whether to buy medical services for their children, they must be told the truth about safety, effectiveness, and alternatives.^[3]

Allegations: Hidden Risks, Dropped Age Limits, and “Lifesaving” Claims

The complaint describes a pattern that many conservative parents have long suspected.^[1]^[4] Regulators say WPATH labeled almost every major intervention for gender-distressed youth as “medically necessary,” a term that helps ensure insurers will pay for the procedures.^[1]^[5] At the same time, the group allegedly failed to clearly disclose serious side effects of cross-sex hormones, including mood problems, pelvic and genital pain, sexual dysfunction, and incontinence.^[1]^[4] Those harms go far beyond the glossy “affirmation” language parents often hear in clinic brochures.

The lawsuit also points to a key change in WPATH’s 2022 Standards of Care, version 8.^[1] In that document, WPATH removed explicit age limits for surgeries such as breast removal and genital operations on minors.^[1] The complaint says this was not driven by new medical evidence but still opened the door for more aggressive procedures on younger teens.^[1] Federal lawyers say clinicians then used WPATH’s language to tell parents these treatments were “lifesaving,” even asking some if they “would rather have a live daughter or a dead son.”^[1]^[4]

Evidence Fight: Weak Science or Expert Consensus?

The case turns on a basic question: were these bold claims backed by real science, or by ideology dressed up as expertise? The lawsuit leans on major reviews, including ones commissioned in the United Kingdom and by the Trump administration, which found the evidence for youth gender transition to be low quality and uncertain.^[5]^[8] The Federal Trade Commission says there is no competent and reliable scientific evidence that puberty blockers, hormones, or surgeries reduce suicide risk in minors, despite how often that promise is used to pressure parents.^[1]

WPATH insists it did things by the book. The group’s own methodology documents say the Standards of Care were developed by a large, multidisciplinary team using systematic evidence reviews, expert discussion, and consensus.^[8]^[11] WPATH describes its guidance as “evidence-informed” recommendations for clinicians, not a commercial product, and argues that the Federal Trade Commission is trying to police medical judgment and professional speech.^[8]^[2] In earlier litigation, WPATH said the agency has “no place interfering with individualized medical decision-making.”^[2]

Why This Matters for Parents, Doctors, and the Constitution

This fight is about more than one medical group. The Federal Trade Commission has long used consumer-protection law to crack down on health claims that are misleading, unproven, or sold with missing risk information.^[21] In health care, the agency looks at what a claim really tells ordinary people, whether that message is true, and whether it matters for choices about buying a service.^[18] When claims involve children’s health and permanent body changes, regulators treat them as especially serious.^[20]

FTC alleges influential transgender health organization misled parents about safety of youth treatments | Brittany Miller, Fox News

The Federal Trade Commission (FTC) and four Republican-led states sued the World Professional Association for Transgender Health (WPATH) on… https://t.co/lqXGwr3faT pic.twitter.com/nz5mFCqeY3

— Owen Gregorian (@OwenGregorian) June 18, 2026

Now that same consumer-fraud framework is being applied to the heart of the gender-medicine debate. For conservatives, the case raises two big issues at once. First, it shines a light on an industry that has rushed children into life-altering drugs and surgeries while branding doubting parents as bigots. Second, it tests how far a federal agency can go in challenging powerful medical groups when their “standards” look more like advocacy and marketing than sober science. However the courts rule, this lawsuit signals that, under President Trump, Washington is no longer giving the child sex-change industry a free pass.